Perspective Therapeutics (NYSE:CATX) Raised to Strong-Buy at Lifesci Capital

Perspective Therapeutics (NYSE:CATX) was upgraded by equities researchers at Lifesci Capital to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Other research analysts also recently issued reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 24th. Oppenheimer reduced their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Finally, Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.13.

Perspective Therapeutics Trading Down 3.3 %

NYSE CATX opened at $2.61 on Thursday. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05. The company’s fifty day moving average price is $3.21 and its two-hundred day moving average price is $7.76.

Institutional Trading of Perspective Therapeutics

Large investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after acquiring an additional 298,778 shares during the period. WealthPlan Investment Management LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter worth about $4,530,000. State Street Corp increased its holdings in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares during the period. Finally, FMR LLC increased its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.